Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| CAL-85-1 | Doxorubicin | Chemo | Chemotherapy | 0.0055249 | -0.3783 | 0.8476 | 0.2160 | 1.2228 | 0.008362 | 0.98762 |
| HCC1428 | Topotecan | Topo I | Chemotherapy | 0.010613 | -0.3764 | 0.8345 | 0.1405 | 0.6324 | 0.02202 | 0.8529 |
| Hs 578T | Taxol | Chemo | Chemotherapy | 0.0010154 | -0.3752 | 0.9535 | 0.4788 | 1.2811 | 0.0015458 | 0.95438 |
| BT-20 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.018077 | -0.3749 | 0.7363 | 0.2005 | 0.7541 | 0.028401 | 0.95352 |
| HCC1954 | Luminespib | HSP90 | Misc | 0.010331 | -0.3745 | 0.6188 | 0.2958 | 2.6936 | 0.012628 | 0.99618 |
| MDA-MB-453 | Pictilisib | pan PI3K | PI3K/mTOR | 0.45409 | -0.3736 | 0.3924 | 0.0999 | 0.7355 | 1.4609 | 0.99053 |
| SK-BR-3 | Buparlisib | pan PI3K | PI3K/mTOR | 0.13982 | -0.3731 | 0.5845 | 0.1589 | 0.9631 | 0.2774 | 0.98702 |
| HCC1419 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0054867 | -0.3722 | 0.6345 | 0.0796 | 0.8272 | 0.0093689 | 0.98036 |
| PDX1328 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0028919 | -0.3715 | 0.7187 | 0.0739 | 0.8875 | 0.004646 | 0.98005 |
| HCC1143 | AZD7762 | CHK1/2 | Cell cycle | 0.05422 | -0.3693 | 0.6563 | 0.2192 | 1.8612 | 0.067869 | 0.988 |
| SUM1315MO2 | Buparlisib | pan PI3K | PI3K/mTOR | 0.40124 | -0.3686 | 0.4388 | 0.1149 | 0.9148 | 0.94031 | 0.98014 |
| HCC1806 | Cisplatin | Chemo | Chemotherapy | 0.82764 | -0.3648 | 0.3231 | 0.1009 | 1.1777 | 1.5296 | 0.98889 |
| HCC1954 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0070107 | -0.3632 | 0.9490 | 0.3748 | 1.0954 | 0.010784 | 0.99379 |
| HCC1937 | AZD7762 | CHK1/2 | Cell cycle | 0.166 | -0.3625 | 0.4881 | 0.1939 | 1.0122 | 0.26931 | 0.9768 |
| MDA-MB-231 | Cediranib | VEGFR/cKIT | RTK | 5.0964 | -0.3620 | 0.1160 | 0.0659 | 2.7537 | 7.595 | 0.99835 |
| T47D | Doxorubicin | Chemo | Chemotherapy | 0.0018887 | -0.3611 | 0.9189 | 0.1014 | 1.2268 | 0.0024801 | 0.96538 |
| PDXHCI002 | Dinaciclib | pan CDK | Cell cycle | 0.012194 | -0.3607 | 0.6030 | 0.2029 | 4.6252 | 0.01372 | 0.99728 |
| CAL-51 | Dinaciclib | pan CDK | Cell cycle | 0.014709 | -0.3585 | 0.5985 | 0.2374 | 3.5319 | 0.017105 | 0.99939 |
| HME1 | Ceritinib | ALK | RTK | 0.82116 | -0.3557 | 0.3036 | 0.1273 | 1.8255 | 1.1186 | 0.99521 |
| SK-BR-3 | Tivantinib | MET | RTK | 0.27263 | -0.3523 | 0.4830 | 0.2060 | 2.4177 | 0.34098 | 0.99571 |
| MDA-MB-361 | Cisplatin | Chemo | Chemotherapy | 2.6294 | -0.3498 | 0.1809 | 0.0253 | 2.1659 | 3.6196 | 0.98908 |
| SK-BR-3 | Volasertib | PLK | Cell cycle | 0.0054419 | -0.3494 | 0.7044 | 0.2799 | 4.1140 | 0.0060939 | 0.9976 |
| MDA-MB-453 | Doxorubicin | Chemo | Chemotherapy | 0.0058313 | -0.3476 | 0.7915 | 0.1805 | 1.7510 | 0.0071438 | 0.98132 |
| Hs 578T | Doxorubicin | Chemo | Chemotherapy | 0.0041078 | -0.3466 | 0.8007 | 0.2450 | 1.2269 | 0.0052684 | 0.96807 |
| CAL-85-1 | Taxol | Chemo | Chemotherapy | 0.0027273 | -0.3464 | 0.7931 | 0.3351 | 2.0210 | 0.0033785 | 0.95638 |